Shares of Heron Therapeutics (HRTX) are rising, up 4.77% to $30.87 after JMP Securities increased its price target to $33 from $25 while maintaining its "outperform" rating.
"We increase our price target based on a risk-adjusted, discounted cash flow analysis driven by a higher valuation for the pain program HTX-011," JMP Securities analysts said.
The upcoming, placebo-controlled Phase 2 bunionectomy study will show improved pain control with HTX-011 over two to three days, compared to PCRX's Exparel Phase 3 data, according to the analyst note.
The company believes that 5% penetration into eligible surgical procedures is reasonable, and assuming 40 million procedures at today's Exparel price implies $500 million in U.S. sales, JMP Securities added.
Heron Therapeutics is a biotechnology company that uses its technology to develop products to address unmet medical needs and to improve the therapeutic profile of injectable pharmaceuticals.
For more on Heron, click hereHRTX data by YCharts